Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.

ABSTRACT:

Background

Effective therapeutic options are limited for patients with advanced esophageal squamous cell carcinoma (ESCC). The incorporation of an immune checkpoint inhibitor and a molecular anti-angiogenic agent into the commonly adopted chemotherapy may produce synergistic effects. Therefore, we aimed to investigate the efficacy and safety of camrelizumab plus apatinib combined with chemotherapy as the first-line treatment of advanced ESCC.

Methods

In this single-arm prospective phase II trial, patients with unresectable locally advanced or recurrent/metastatic ESCC received camrelizumab 200 mg, liposomal paclitaxel 150 mg/m² , and nedaplatin 50 mg/m² on day 1, and apatinib 250 mg on days 1-14. The treatments were repeated every 14 days for up to 9 cy

SUBMITTER: Zhang B 

PROVIDER: S-EPMC7743020 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature